ArticlePediatric cardiology2026

Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia.

Yuto Sunaga et al.PubMed ↗Publisher ↗

No numbers read from the abstract.